Evidence map›Paper›PMID 33803197›Full record

ArticleNutrients2021

Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells.

Francesca Lombardi, Francesca Rosaria Augello, Paola Palumbo, Elona Mollsi, Maurizio Giuliani, Anna Maria Cimini, Maria Grazia Cifone, Benedetta Cinque

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Prospective therapeutics for intestinal and hepatic fibrosis.Bioengineering & translational medicine · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Francesca LombardiDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.ORCID 0000-0002-0551-5076
Francesca Rosaria AugelloDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.ORCID 0000-0001-5907-7078
Paola PalumboDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.ORCID 0000-0001-7027-2691
Elona MollsiDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.
Maurizio GiulianiDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.ORCID 0000-0002-1465-9637
Anna Maria CiminiDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.ORCID 0000-0002-2737-7970
Maria Grazia CifoneDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.
Benedetta CinqueDepartment of Life, Health & Environmental Sciences, University of L'Aquila, Via Pompeo Spennati, Building Rita Levi Montalcini, Coppito, 67100 L'Aquila, Italy.
University of L'Aquila · IT

Funding

Università degli Studi dell'Aquila and RIA-SP/2020Università degli Studi dell'Aquila RIA-MCM/2020
6 · The paper itself

Abstract

Fibrosis is a severe complication of chronic inflammatory disorders, such as inflammatory bowel disease (IBD). Current strategies are not fully effective in treating fibrosis; therefore, innovative anti-fibrotic approaches are urgently needed. TGF-β1 plays a central role in the fibrotic process by inducing myofibroblast differentiation and excessive extracellular matrix (ECM) protein deposition. Here, we explored the potential anti-fibrotic impact of two high concentration multi-strain probiotic formulations on TGF-β1-activated human intestinal colonic myofibroblast CCD-18Co. Human colonic fibroblast CCD-18Co cells were cultured in the presence of TGF-β1 to develop a fibrotic phenotype. Cell viability and growth were measured using the Trypan Blue dye exclusion test. The collagen-I, α-SMA, and pSmad2/3 expression levels were evaluated by Western blot analysis. Fibrosis markers were also analyzed by immunofluorescence and microscopy. The levels of TGF-β1 in the culture medium were assessed by ELISA. The effects of commercially available probiotic products VSL#3

Indexed as

Bacterial LysatesCell DifferentiationCell ExtractsCell Growth ProcessesCells, CulturedCell SurvivalExtracellular Matrix ProteinsFibrosisHumansInflammatory Bowel DiseasesIntestinal DiseasesIntestinesMyofibroblastsPhenotypeProbioticsSignal TransductionBacterial LysatesBroncho-VaxomCell ExtractsExtracellular Matrix ProteinsTGFB1 protein, humanTransforming Growth Factor beta1CCD-18Co cellscollagen-Iintestinal fibrosisSmad 2/3TGF-β1Vivomixx®VSL#3®α-SMA

Identifiers

PMID33803197
PMCPMC7998462
OpenAlexW3133961301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.